Overview of Dr. Vachhani
Dr. Pankit Vachhani is an oncologist in Birmingham, AL and is affiliated with multiple hospitals in the area, including University of Alabama Hospital and USA Health University Hospital. He received his medical degree from Weill Cornell Medical College in Qatar and has been in practice 5 years. He is one of 65 doctors at University of Alabama Hospital and one of 37 doctors at USA Health University Hospital who specialize in Oncology. He has more than 50 publications and over 500 citings.
Office
619 19th St S
Birmingham, AL 35249Fax+1 205-975-7837- Is this information wrong?
Education & Training
- University at BuffaloFellowship, Hematology and Medical Oncology, 2018
- Virginia Commonwealth University Health SystemResidency, Internal Medicine, 2012 - 2015
- Weill Cornell Medical College in QatarClass of 2012
Certifications & Licensure
- AL State Medical License 2018 - 2024
- VA State Medical License 2012 - 2015
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- NTX-301 in MDS/AML Start of enrollment: 2021 Jan 06
Publications & Presentations
PubMed
- Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.Garrett Bourne, Kendall Diebold, Manuel Espinoza-Gutarra, Zaid Al-Kadhimi, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Ravi Bhatia, Omer Jamy> ;Leukemia Research. 2024 Feb 28
- SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis.Vachhani, P., Loghavi, S., Bose, P.> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Jan 21
- Interferons in the treatment of myeloproliferative neoplasms.Pankit Vachhani, John Mascarenhas, Prithviraj Bose, Gabriela Hobbs, Abdulraheem Yacoub, Jeanne M Palmer, Aaron T Gerds, Lucia Masarova, Andrew T Kuykendall, Raajit K R...> ;Therapeutic Advances in Hematology. 2024 Jan 1
- Join now to see all
Journal Articles
- Intensive Chemotherapy vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center ExperiencePankit Vachhani, Evelena P Ontiveros, Leukemia Research
- Intensive Chemotherapy vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center ExperiencePankit Vachhani, Evelena P Ontiveros, Leukemia Research
Abstracts/Posters
- Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE¬ (Bispecific T-Cell Engager) in Patients with R...Pankit Vachhani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First RemissionClinically Relevant AbstractPankit Vachhani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Authored Content
- Intensive Chemotherapy vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center ExperienceOctober 2018
Press Mentions
- UAB Named Center of Excellence in Mast Cell DiseasesFebruary 1st, 2023
Hospital Affiliations
- University of Alabama HospitalBirmingham, Alabama
- USA Health University HospitalMobile, Alabama
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: